Radioimmunotherapy with 131I-Rituximab in a Patient with Diffuse Large B-Cell Lymphoma Relapsed After Treatment with 90Y-Ibritumomab Tiuxetan

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations

Medicine, Immunology, Oncology +14

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Mark Kaminski, Andrew D. Zelenetz, Oliver W. Press et al. · Journal of Clinical Oncology · 2001 · 586 citations

Medicine, Oncology, Pharmacology +15

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

Kai Fu, Dennis D. Weisenburger, William W.L. Choi et al. · Journal of Clinical Oncology · 2008 · 337 citations · Full text

Medicine, Hematology, Oncology +15

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation

Franck Morschhauser, Tim Illidge, D. Huglo et al. · Blood · 2007 · 186 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial

Julie M. Vose, Shelly Carter, Linda J. Burns et al. · Journal of Clinical Oncology · 2013 · 176 citations · Full text

Medicine, Hematology, Oncology +17